Triple A schreef op 13 december 2022 19:54:
[...]
Ik weet niet waar jij dat gelezen hebt ????
Op 4 november 2022 presenteerde Galapagos onder Stoffels de nieuwe strategie:
Guiding principles for a sustainable future:- Invest in strategic therapeutic areas of oncology and immunology
- Rebuild and accelerate portfolio of transformational medicines in high unmet medical needs
- Combine internal with external innovation
Capital allocation:- Discontinue fibrosis and kidney disease to further invest in oncology
- Leverage strong balance sheet through disciplined cash management and smart business development
Oncology roadmap:- Validate point-of-care CAR-T delivery model with proven CD191 and BCMA2
- Develop next-generation, best-in-class oncology candidates
Immunology roadmap:- Evaluate potential of filgotinib in axial spondyloarthritis
- Execute on TYK2i clinical program with ‘3667
- Continue to invest in deep portfolio across modes of action, with JAKi, TYK2i and SIKi programs
Commercial roadmap:- Jyseleca® 2022 net sales guidance further upped to €80-€90 million
- Leverage commercial infrastructure for future launches
=========================================
Bovenstaand lijkt mij redelijk tegen te spreken wat jij beweert.
-